Neurocrine Biosciences Inc (NASDAQ:NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.
Sales reached $805.5 million, beating the consensus of $792.47 million.
Fourth-quarter net product sales were $798.3 million, up 29% year over year.
Ingrezza (drug for involuntary movements) fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion, reflecting 7% and 9% growth year-over-year, respectively.
Results reflected double-digit prescription volume growth in TRx and NRx, driven by strong patient demand, partially offset by a lower net price due to new formulary access investments to support long-term growth.
Crenessity (classic congenital adrenal hyperplasia drug) fourth-quarter and full-year 2025 net product sales were $135.3 million and $301.2 million, reflecting 431 and 2,048 total new patient enrollment start forms, respectively, driven by strong patient demand …